Prestige BioPharma프레스티지바이오파마
950210 · KOSPI · ₩950210 · 프레스티지바이오파마
₩5,050▼ ₩10 (0.20%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩10M | ₩517,114 | ₩122,410 | ₩0 | ₩0 |
| Cost of sales | ₩19M | — | — | — | — |
| Gross profit | −₩9M | — | — | — | ₩0 |
| Operating income | −₩48M | −₩47M | −₩53M | −₩49M | −₩16M |
| Net income | ₩3M | −₩41M | −₩2.2M | −₩176M | −₩6.5M |
| Net income to shareholders | ₩16M | −₩25M | ₩13M | −₩176M | −₩6.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩550M | ₩512M | ₩565M | ₩387M | ₩535M |
| Current assets | ₩155M | ₩180M | ₩237M | ₩241M | ₩407M |
| Cash and equivalents | ₩85M | ₩158M | ₩95M | ₩208M | ₩406M |
| Total liabilities | ₩175M | ₩141M | ₩149M | ₩54M | ₩26M |
| Current liabilities | ₩122M | ₩105M | ₩103M | ₩32M | ₩12M |
| Borrowings | ₩105M | ₩63M | ₩62M | ₩0 | ₩0 |
| Total equity | ₩375M | ₩371M | ₩416M | ₩333M | ₩509M |
| Shareholders' equity | ₩303M | ₩316M | ₩343M | ₩333M | ₩509M |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩37M | −₩36M | −₩46M | −₩38M | −₩14M |
| Capital spending | ₩29M | ₩15M | ₩37M | ₩47M | ₩835,550 |
| Free cash flow | −₩66M | −₩51M | −₩82M | −₩85M | −₩14M |
Consolidated where available. Amounts in won.
Also known as: Prestige BioPharma / 프레스티지바이오파마 / 950210 / KRX:950210
Source: KRX statistical information